The stream · Daily digest
The stream: Wednesday, October 28, 2026
12 briefs from ClinicalTrials.gov and the Federal Register, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 8
-
Ray Therapeutics registers Phase 2/3 trial of RTx-015 in retinitis pigmentosa
The study plans to enroll 60 participants and is expected to start in October 2026, with primary completion projected for October 2028. It aims to evaluate the effectiveness and safety of a single intravitreal injection of the investigational gene therapy RTx-015 in participants with retinitis pigmentosa.
Source: ClinicalTrials.gov registry record, October 28, 2026
-
Biohaven registers Phase 2b/3 study of BHV-1300 in Graves' Disease
The study, led by Biohaven Therapeutics Ltd., plans to enroll an estimate of 356 participants to evaluate the safety and tolerability of BHV-1300 in adults with Graves' Disease. It plans to start in October 2026 and reach primary completion in December 2028.
Source: ClinicalTrials.gov registry record, October 28, 2026
-
Precigen registers Phase 3 study of zopapogene imadenovec in pediatric RRP
The study, led by Precigen, Inc., plans to enroll 15 participants and has a planned start date of December 31, 2026, with a planned primary completion date of January 2029. It plans to assess the safety and efficacy of zopapogene imadenovec, an investigational immunotherapy, in children with recurrent respiratory papillomatosis.
Source: ClinicalTrials.gov registry record, October 28, 2026
-
Hoffmann-La Roche posts results of Phase III astegolimab trial in COPD
The study enrolled 1380 participants and completed primary data collection on June 24, 2025. Results were first posted on ClinicalTrials.gov on October 28, 2026.
Source: ClinicalTrials.gov results record, October 28, 2026
-
DBV Technologies posts results of Phase 3 DBV712 study in peanut-allergic children
The study, completed with 304 participants, posted results on ClinicalTrials.gov on October 28, 2026. It was an open-label extension of the EPITOPE study evaluating long-term clinical benefit and safety of DBV712 in peanut-allergic children.
Source: ClinicalTrials.gov results record, October 28, 2026
-
Bausch Health posts results of Phase 3 rifaximin SSD study in cirrhosis
The study, completed in February 2026, enrolled 517 participants and evaluated rifaximin SSD-40mg IR for delaying the first episode of overt hepatic encephalopathy in patients with liver cirrhosis. Results were first posted on ClinicalTrials.gov on October 28, 2026.
Source: ClinicalTrials.gov results record, October 28, 2026
-
Amgen posts results of Phase 3 erenumab trial in pediatric chronic migraine
The study, completed with 284 participants, evaluated erenumab in children 6 to <12 years and adolescents 12 to <18 years with chronic migraine. Results were first posted on ClinicalTrials.gov on October 28, 2026.
Source: ClinicalTrials.gov results record, October 28, 2026
-
Apellis posts results of Phase 3 extension study of pegcetacoplan in geographic atrophy
The study enrolled 792 participants and completed primary data collection on September 5, 2025. Results were first posted on ClinicalTrials.gov on October 28, 2026.
Source: ClinicalTrials.gov results record, October 28, 2026
Regulation · 4
-
CMS finalizes 2027 ESRD PPS rule with $297.52 base rate
On Oct. 28, 2026, CMS issued a final rule that sets the 2027 ESRD PPS base rate at $297.52, an increase of $15.81 from the 2026 rate, and projects a 2.7% rise in total payments to about 7,600 facilities. The rule also updates phosphate binder inclusion, low-volume and pediatric payment adjustments, and the home and self-dialysis training add-on payment.
Source: CMS fact sheet, October 28, 2026
-
Sales of Leqembi total 32.2 billion yen in third quarter 2026
BioArctic AB reported preliminary global revenue for Leqembi of JPY 32.2 billion in the third quarter 2026, generating a royalty of SEK 203.8 million, up about 74 percent from the same period in 2025. The company disclosed the figures under the EU Market Abuse Regulation on October 28 2026.
Source: Company press release (PR Newswire), October 28, 2026
-
FDA issues priority review voucher for EMCITATE (tiratricol)
The FDA announced that EMCITATE (tiratricol), approved September 28, 2026, manufactured by Rare Thyroid Therapeutics International AB, meets the criteria for a priority review voucher. The tablet is indicated for treating peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 deficiency (Allan-Herndon-Dudley syndrome).
Source: Federal Register notice, October 28, 2026
-
FDA releases draft guidance on electronic IDE submission template
Comments on the draft guidance are due by December 28, 2026. The guidance targets sponsors filing IDE applications with the Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research.
Source: Federal Register notice, October 28, 2026